Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Regulatory News (RB.)

  • There is currently no data for RB.

Directorate Change

23 Jan 2015 11:11

RNS Number : 9969C
Reckitt Benckiser Group PLC
23 January 2015
 



23 January 2015

DIRECTORATE CHANGE

 

Reckitt Benckiser Group plc (RB) today announces the following appointments to the Board as independent Non-Executive Directors, effective 10 February 2015:

 

Mary Harris

Mary has been Non-Executive Director at J Sainsbury plc since 2007, and currently chairs the Remuneration Committee. She is also a member of the Supervisory Boards of Unibail-Rodamco SE, TNT Express NV and Scotch and Soda NV. In 2014, she was appointed a Non-Executive Director at ITV plc. Until 2011, Mary was also a member of the Advisory Board of Irdeto BV.

 

Mary has previously worked as a Partner at McKinsey & Company with a particular focus on consumer and retail businesses in China, South East Asia, and Europe. Mary will bring to the Board a top-level strategic outlook, with international and consumer focus. 

 

She is also a graduate of the University of Oxford (MA Politics, Philosophy and Economics) and from Harvard Business School, where she graduated with an MBA.

 

Dr. Pamela Kirby

Pam is Chairman of Scynexis, Inc., and also serves as a Non-Executive Director on the Boards of DCC plc, Victrex plc and Hikma Pharmaceuticals PLC. Until 2014, Pam had long-standing Non-Executive Director appointments at Informa plc and at Smith & Nephew plc and was also a Non-Executive Director of Novo Nordisk from 2008 - 2011. She has also previously served as a member of the Advisory Board of law firm Simmonds and Simmonds.

During her executive career she held the position of Chief Executive Officer of Quintiles Transnational Corporation. Additionally, she has held senior positions at AstraZeneca PLC and Hoffman-La Roche.

Pam has a BSc in Pharmacology and a Ph.D. in Clinical Pharmacology from the University of London. Her exceptional understanding of both commerce and healthcare make her a valuable addition to our Board.

Christopher A. Sinclair

Chris is currently the Independent Lead Director and Chairman of the Audit and Executive Committees of Mattel, Inc, where he has served on the Board since 1996.

Chris has also served as Executive Chairman of Scandent Holdings, Executive Chairman and Chief Executive Officer of Cambridge Solutions Ltd, Chairman and Chief Executive Officer of Caribiner International, and President and Chief Executive Officer at Quality Foods Centers, Inc. Earlier in his career, Chris held various senior management positions with PepsiCo, including Chairman and CEO of Pepsi Cola Co., and Chairman of PepsiCo International Foods and Beverages, which gave him the platform to showcase his strong global branding skills.

Chris has a bachelor's degree in Business Administration from the University of Kansas and an MBA from the Tuck School at Dartmouth College.

Adrian Bellamy, Chairman of RB, commented:

 

"We are delighted that Mary, Pam and Chris have all agreed to join the RB Board. Their high intellectual and strategic capabilities, along with their proven leadership and commercial experience across a host of markets, will make them fantastic additions to the RB Board and will help us deliver our strategy and meet the challenges and opportunities that 2015 and beyond will bring."

 

No further disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of these appointments.

 

For Further Information

William R. Mordan

Company Secretary

Richard Joyce

Director, Investor Relations

 

Telephone +44 (0) 1753 217 800

 

About RB:

 

RB* is the world's leading consumer health and hygiene company. The company has operations in over 60 countries, with headquarters in the UK, Singapore, Dubai and Amsterdam, and sales in almost 200 countries. The company employs approximately 37,000 people worldwide.

With a purpose of delivering innovative solutions for healthier lives and happier homes, RB is in the top 20 of companies listed on the London Stock Exchange. Today it is the global No 1or No 2 in the majority of its fast-growing categories, driven by an exceptional rate of innovation. Its health, hygiene and home portfolio is led by 19 global Powerbrands of Nurofen, Strepsils Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Bang, Mortein, Finish, Vanish, Calgon, Air Wick, Woolite and French's. At the start of 2014 RB had 43% of its core revenues coming from its 2 emerging market Areas and 57% from its developed market Area; 72% of core revenues came from the health and hygiene categories of the portfolio.

 

Fuelled by a new breed of talent who blend intellectual curiosity with commitment to the highest quality standards, RB is set to redefine the world of consumer health and hygiene. RB people and its culture are at the heart of the company's success. They have an intense drive for achievement and a desire to outperform wherever they focus, including in sustainability where the company is targeting a 1/3 reduction in water impact, 1/3 reduction in carbon and to have 1/3 of its net revenue coming from more sustainable products by 2020. It is also the Save the Children charity's largest FMCG global partner, with a new partnership vision to radically reduce the world's second biggest killer of under-fives, diarrhoea. Overall RB wants to reach 200 million people to improve their health and hygiene behaviour.

 

For more information visit www.rb.com 

 

*RB is the trading name of Reckitt Benckiser group of companies

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUUGGUPAGGW
Date   Source Headline
31st Mar 202110:00 amRNSRB rebrands as Reckitt
26th Mar 202112:30 pmRNSDirector/PDMR Shareholding
17th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20212:30 pmRNSDirector/PDMR Shareholding
3rd Mar 202110:00 amRNSDirector/PDMR Shareholding
1st Mar 20213:00 pmRNSDirector/PDMR Shareholding
1st Mar 20212:16 pmRNSTotal Voting Rights
25th Feb 20213:20 pmRNSDirector/PDMR Shareholding
24th Feb 20217:01 amRNSAcquisition
24th Feb 20217:01 amRNSDisposal
24th Feb 20217:00 amRNSFinal Results
1st Feb 202111:42 amRNSTotal Voting Rights
4th Jan 202112:39 pmRNSTotal Voting Rights
30th Dec 20209:21 amRNSTR-1: Notification of major holdings
17th Dec 202010:45 amRNSDirectorate Change
1st Dec 202011:30 amRNSTotal Voting Rights
25th Nov 202011:30 amRNSDirector/PDMR Shareholding
23rd Nov 20204:30 pmRNSDirector/PDMR Shareholding
2nd Nov 202011:10 amRNSTotal Voting Rights
21st Oct 20202:00 pmRNSDirector/PDMR Shareholding
20th Oct 20204:35 pmRNSPrice Monitoring Extension
20th Oct 20207:00 amRNS3rd Quarter Results
7th Oct 20203:00 pmRNSDirector Declaration
5th Oct 20204:00 pmRNSDirector/PDMR Shareholding
1st Oct 20202:34 pmRNSDirector/PDMR Shareholding
1st Oct 202011:38 amRNSTotal Voting Rights
1st Sep 202010:22 amRNSTotal Voting Rights
26th Aug 20201:05 pmRNSDisclosure of rights attached to equity shares
25th Aug 20204:00 pmRNSDirector/PDMR Shareholding
3rd Aug 202012:08 pmRNSTotal Voting Rights
28th Jul 20207:00 amRNSHalf-year Report
1st Jul 20209:17 amRNSTotal Voting Rights
30th Jun 20205:00 pmRNSDirector Declaration
23rd Jun 202010:00 amRNSDirectorate Change
5th Jun 20204:30 pmRNSDirector/PDMR Shareholding
1st Jun 202011:01 amRNSTotal Voting Rights
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
29th May 20204:30 pmRNSDirector/PDMR Shareholding
29th May 202012:20 pmRNSDirector/PDMR Shareholding
28th May 20202:29 pmRNSDirector/PDMR Shareholding
13th May 20205:46 pmRNSDirector/PDMR Shareholding
13th May 20202:07 pmRNSPublication of Offering Memorandum
12th May 20206:01 pmRNSIssue of Debt
12th May 20204:55 pmRNSResult of AGM
12th May 20204:15 pmRNSDirectorate Change
4th May 20202:10 pmRNSDirector/PDMR Shareholding
1st May 20204:41 pmRNSDirector/PDMR Shareholding
1st May 202011:38 amRNSTotal Voting Rights
30th Apr 20207:00 amRNSQ1 2020 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.